Study uncovers a gene that strongly associates with breast cancer patient's treatment outcomes
A multidisciplinary team of researchers from Roswell Park Comprehensive Cancer Center and Kaiser Permanente Northern California have identified the first pharmacogenomic marker for anthracyclines and HER2-targeting drugs, two commonly used breast cancer chemotherapies.
Source: news-medical.net